首页> 外文期刊>Der Pharmacia Lettre >Formulation and evaluation of bilayered tablets of sumatriptan succinate byusing hydrophilic polymers
【24h】

Formulation and evaluation of bilayered tablets of sumatriptan succinate byusing hydrophilic polymers

机译:亲水性聚合物制备舒马曲坦琥珀酸酯双层片剂

获取原文
           

摘要

Bi-layered [1] tablet refers to tablet which contain subunits. In bi-layer [2] tablets, one layer tablet provides immediate release and the other layer acts as sustained release. Sumatriptan is a new class of anti-migraine [3] drugs that selectively activate 5-HT1B/1D receptors and are called triptans. Our objective is to formulate and evaluate the bi-layer tablets of sumatriptan succinate of dose 250mg an anti-migraine drug. In the present case 50 mg of Sumatriptan succinate has to be released immediately and the remaining 200 mg of Sumatriptan succinate has to be released in a sustained manner. The formulations is optimized [4] by incorporating varying composition of polymers such as Sodium alginate, Hydroxy propyl methyl cellulose E15 and Hydroxy propyl methyl cellulose K15.All the excipients are tested for compatibility with model drug. The pre-formulation parameters such as Tapped density, Bulk density, Compressibility index, Hausner’s ratio and Angle of repose were analyzed. The Thickness, Hardness, Friability, Disintegration time, Weight variation and Content uniformity was evaluated for core tablets. The In-vitro drug release was performed by using dissolution apparatus-II (USP paddle type) by maintaining temperature of 37oC ± 5oC. Based on the dissolution result F2 trial formulation (containing HPMC E15 and Sodium alginate) was selected as best formulation. The drug release of F2 follows zero-order. The total amount of drug released from the Formulation 2 is the maximum and it reached to about 99.89%.
机译:双层[1]片剂是指含有亚基的片剂。在双层[2]药片中,一层药片可立即释放,另一层药片可持续释放。舒马曲坦是一类新型的抗偏头痛药物[3],可选择性激活5-HT1B / 1D受体,被称为曲普坦。我们的目标是配制和评估舒马曲坦琥珀酸酯双层片剂,剂量为250mg抗偏头痛药物。在当前情况下,必须立即释放50 mg的舒马曲坦琥珀酸酯,而其余的200 mg的舒马曲坦琥珀酸酯则必须持续释放。通过掺入不同成分的聚合物(例如海藻酸钠,羟丙基甲基纤维素E15和羟丙基甲基纤维素K15)来优化配方[4]。测试了所有赋形剂与模型药物的相容性。分析了配制前的参数,如堆积密度,堆积密度,可压缩性指数,豪斯纳比和休止角。评价了片芯的厚度,硬度,脆性,崩解时间,重量变化和含量均匀性。通过使用溶出度仪-II(USP桨式)在37oC±5oC的温度下进行体外药物释放。根据溶解结果,选择F2试验配方(包含HPMC E15和海藻酸钠)作为最佳配方。 F2的药物释放遵循零级。从制剂2释放的药物总量最大,达到约99.89%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号